Difference between revisions of "Eberhart 2009 Leukemia"
(Created page with "{{Publication |title=Eberhart K, Renner K, Ritter I, Kastenberger M, Singer K, Hellerbrand C, Kreutz M, Kofler R, Oefner PJ (2009) Low doses of 2-deoxy-glucose sensitize acute ly...") |
|||
| (11 intermediate revisions by 6 users not shown) | |||
| Line 1: | Line 1: | ||
{{Publication | {{Publication | ||
|title=Eberhart K, Renner K, Ritter I, Kastenberger M, Singer K, Hellerbrand C, Kreutz M, Kofler R, Oefner PJ (2009) Low doses of 2-deoxy-glucose sensitize acute lymphoblastic leukemia cells to glucocorticoid-induced apoptosis. Leukemia 23: 2167- | |title=Eberhart K, Renner K, Ritter I, Kastenberger M, Singer K, Hellerbrand C, Kreutz M, Kofler R, Oefner PJ (2009) Low doses of 2-deoxy-glucose sensitize acute lymphoblastic leukemia cells to glucocorticoid-induced apoptosis. Leukemia 23:2167-70. | ||
|authors=Eberhart K, Renner K, Ritter I, Kastenberger M, Singer K, Hellerbrand C, Kreutz M, Kofler R, Oefner PJ | |info=[http://www.ncbi.nlm.nih.gov/pubmed/19657369 PMID: 19657369]; [http://www.nature.com/leu/journal/v23/n11/full/leu2009154a.html Open Access] | ||
|authors=Eberhart K, Renner K, Ritter I, Kastenberger M, Singer K, Hellerbrand C, Kreutz M, Kofler R, Oefner PJ | |||
|year=2009 | |year=2009 | ||
|journal=Leukemia | |journal=Leukemia | ||
| | |abstract=Glucocorticoids (GCs) are an essential component of most chemotherapy protocols for lymphoid malignancies, particularly childhood acute lymphoblastic leukemia (ALL).1, 2 Nevertheless, adverse side effects of GCs call for improved therapy protocols. | ||
GCs decrease the activity of glycolytic enzymes3 and upregulate the expression of the glycolytic regulator, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase ''in vitro'' and ''in vivo''.4 This led us to investigate whether co-administration of 2-deoxy-glucose (2-DG), an inhibitor of glycolysis, systemic application of which up to a blood concentration of approximately 3 mM had caused a transient hyperglycemia only,5 might potentiate the apoptotic effect of GC. | |||
|mipnetlab=DE Regensburg Renner-Sattler K, DE Regensburg Renner-Sattler K | |||
}} | }} | ||
{{Labeling | {{Labeling | ||
|area=Respiration | |||
|diseases=Cancer | |||
|organism=Human | |||
|tissues=Blood cells, Lymphocyte | |||
|preparations=Intact cells | |||
|couplingstates=LEAK, ROUTINE, ET | |||
|pathways=ROX | |||
|instruments=Oxygraph-2k | |instruments=Oxygraph-2k | ||
| | |additional=Leukemia, | ||
}} | }} | ||
Latest revision as of 18:17, 31 January 2020
| Eberhart K, Renner K, Ritter I, Kastenberger M, Singer K, Hellerbrand C, Kreutz M, Kofler R, Oefner PJ (2009) Low doses of 2-deoxy-glucose sensitize acute lymphoblastic leukemia cells to glucocorticoid-induced apoptosis. Leukemia 23:2167-70. |
Eberhart K, Renner K, Ritter I, Kastenberger M, Singer K, Hellerbrand C, Kreutz M, Kofler R, Oefner PJ (2009) Leukemia
Abstract: Glucocorticoids (GCs) are an essential component of most chemotherapy protocols for lymphoid malignancies, particularly childhood acute lymphoblastic leukemia (ALL).1, 2 Nevertheless, adverse side effects of GCs call for improved therapy protocols.
GCs decrease the activity of glycolytic enzymes3 and upregulate the expression of the glycolytic regulator, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase in vitro and in vivo.4 This led us to investigate whether co-administration of 2-deoxy-glucose (2-DG), an inhibitor of glycolysis, systemic application of which up to a blood concentration of approximately 3 mM had caused a transient hyperglycemia only,5 might potentiate the apoptotic effect of GC.
• O2k-Network Lab: DE Regensburg Renner-Sattler K, DE Regensburg Renner-Sattler K
Labels: MiParea: Respiration
Pathology: Cancer
Organism: Human Tissue;cell: Blood cells, Lymphocyte Preparation: Intact cells
Coupling state: LEAK, ROUTINE, ET
Pathway: ROX
HRR: Oxygraph-2k
Leukemia
